May 13, 2026 | Read online

Thursday’s Spotlight: See Why (NASDAQ: GTBP) Just Hit Our Screen For Tomorrow

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Market Maven Insights Puts (NASDAQ: GTBP) #1 On Tomorrow’s Watchlist—Thursday, May 14, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

Our Full Breakdown of (GTBP) Goes Live Early Tomorrow

Pull Up (GTBP) Before Tomorrow Morning…

May 13, 2026
Thursday’s Spotlight: See Why (NASDAQ: GTBP) Just Hit Our Screen For Tomorrow

Dear Reader,

In biotechnology, some of the most interesting stories emerge when a company’s clinical progress begins to accelerate before its valuation reflects the full scope of what is in development.

That is the backdrop now taking shape around GT Biopharma, Inc. (Nasdaq: GTBP).

With shares below $0.50 and a market capitalization under $12M, (GTBP) is advancing a proprietary immunotherapy platform designed to harness natural killer (NK) cells to target can-cer. The company has already reported early proof-of-concept data in patients and is preparing to launch a second clinical program in mid-2026 focused on multiple solid tumor indications.

At the same time, recent momentum has started to bring the story back into focus, with the profile advancing approximately 59% in less than a week.

(GTBP) now has two clinical-stage assets, projected funding into the fourth quarter of 2026, and a broader pipeline spanning hematologic can-cers, solid tumors, and autoimmune disease.

When you combine multiple near-term clinical milestones, a differentiated platform technology, and renewed market attention, (GTBP) stands out as a company worth watching closely heading into Thursday, May 14, 2026.

Engineering Natural Killer Cells to Fight Can-cer

GT Biopharma, (NASDAQ: GTBP) is a clinical-stage immuno-oncology company focused on developing next-generation therapies that harness the power of natural killer (NK) cells—an important part of the immune system that can identify and destroy can-cer cells.

At the center of the company’s approach is its proprietary TriKE® (Tri-Specific Killer Engager) platform. This technology is designed to activate NK cells, stimulate their expansion, and direct them toward specific tumor targets using a single engineered molecule.

(GTBP) holds the exclusive worldwide license from the University of Minnesota to develop and commercialize this platform, which serves as the foundation for a growing pipeline targeting blood can-cers, solid tumors, and autoimmune diseases.

(GTBP)’s lead clinical candidate, GTB-3650, is currently in a Phase 1 dose-escalation trial for relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). GTB-3650 targets CD33, a protein commonly found on certain blood can-cer cells, while simultaneously stimulating NK cells using interleukin-15 (IL-15).

(GTBP) is also preparing to launch GTB-5550, a second clinical-stage TriKE candidate targeting B7-H3, a tumor-associated antigen expressed across multiple solid tumors, including prostate, ovarian, and pancreatic can-cers. The U.S. Food and dr-ug Administration (FDA) cleared the investigational new dr-ug (IND) application for GTB-5550 in early 2026, and the company expects to initiate a Phase 1 basket trial in mid-2026.

Beyond these two core assets, (GTBP) is leveraging its TriKE platform to develop additional NK cell engager therapies for hematologic malignancies, solid tumors, and autoimmune diseases. (GTBP)’s strategy is centered on creating off-the-shelf immunotherapies that may offer a simpler and potentially more scalable alternative to complex cell-based treatments.

A Rapidly Expanding Market for NK Cell-Based Therapies

Can-cer immunotherapy remains one of the largest and fastest-growing segments in biotechnology. Industry forecasts estimate the global immunotherapy market was valued at approximately $136B in 2025 and could reach roughly $367B by 2035, representing a projected compound annual growth rate (CAGR) of about 10.4%.

Within that broader potential, natural killer (NK) cell therapeutics are gaining increasing attention. This segment was valued at approximately $3.2B in 2024 and is projected to reach $8.6B by 2033.

(GTBP)’s lead solid tumor candidate, GTB-5550, is being developed for a portion of the estimated $362B global solid tumor market. The planned Phase 1 basket study is expected to evaluate the therapy across as many as seven metastatic can-cer types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder can-cers.

What differentiates the company’s TriKE® platform is its selective activation of NK cells rather than T cells. This approach is designed to potentially reduce some of the serious toxicities that have been associated with certain cell therapies, including cytokine release syndrome (CRS) and neurological side effects.

Large pharmaceutical companies are increasingly validating the space. According to (GTBP)’s March 2026 corporate presentation, both Sanofi and Gilead Sciences have completed NK cell-related partnerships with total potential values exceeding $1B, highlighting growing industry interest in this emerging therapeutic category.

Recent Developments Accelerating (GTBP) Story

FDA Clears GTB-5550 for Human Testing: In February 2026, (GTBP) announced that the U.S. Food and dr-ug Administration (FDA) cleared the Investigational New dr-ug (IND) application for GTB-5550, the company’s B7-H3-targeted TriKE® therapy for solid tumors. This clearance allows GTBP to begin its first solid tumor clinical trial and marks the third TriKE® candidate to reach the clinic.

Phase 1 Solid Tumor Trial Expected to Begin Mid-2026: Management expects to initiate a Phase 1 basket study of GTB-5550 in mid-2026. The trial is designed to enroll patients across multiple metastatic can-cer types, including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder can-cers.

GTB-3650 Continues Advancing in AML and High-Risk MDS:(GTBP)’s lead blood can-cer program, GTB-3650, remains in an ongoing Phase 1 dose-escalation study for relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). GT Biopharma stated that enrollment is continuing, with the next clinical update anticipated in Q3 2026 after completion of Cohort 5.

ca-sh Runway Extended Through Q4 2026: (GTBP) reported an unaudited pro forma ca-sh balance of approximately $9M as of January 31, 2026, which management believes is sufficient to fund operations through the fourth quarter of 2026.

2026 Positioned as a Multi-Catalyst Year: With GTB-5550 preparing to enter the clinic, GTB-3650 advancing through higher-dose cohorts, and multiple clinical updates expected over the coming quarters, 2026 is shaping up to be a milestone-rich year for the company’s TriKE® platform.

Conference Participation Expands Visibility: In March 2026, (GTBP) announced participation in the 38th Annual Roth Conference, providing management an opportunity to present its clinical progress and strategic outlook to institutional crowds and industry participants.

7 Factors Putting (GTBP) at the Top of Our Watchlist for Thursday, May 14, 2026

1. Momentum Has Returned: (GTBP) has surged approximately 59% in less than a week, pushing the story back onto our radar.

2. Micro-Cap Valuation: With a market capitalization below $12M, the company remains small relative to many clinical-stage biotech peers.

3. Active Clinical Enrollment: GTB-3650 is currently enrolling patients in a Phase 1 study for relapsed or refractory AML and high-risk MDS.

4. Second Program Cleared by FDA: GTB-5550 has received FDA clearance for a planned Phase 1 basket trial expected to begin in mid-2026.

5. Q3 Data Catalyst Ahead: Management expects to provide a new GTB-3650 clinical update in the third quarter of 2026.

6. Broad TriKE® Platform Potential: The company’s proprietary TriKE® technology is designed to direct NK cells against multiple tumor targets.

7. Ca-sh Runway into Q4 2026: Current ca-sh resources are expected to support operations through the fourth quarter of 2026.

Pull Up (GTBP) Before Tomorrow Morning…

GT Biopharma (Nasdaq: GTBP) is beginning to attract attention as several important developments line up at once. The profile has advanced approximately 59% in less than a week, while the company continues enrolling patients in its GTB-3650 Phase 1 study, prepares for a Q3 2026 clinical update, and moves toward the mid-2026 launch of a second FDA-cleared program.

Beyond these near-term milestones, (GTBP)’s proprietary TriKE® platform supports a broader pipeline spanning blood can-cers, solid tumors, and autoimmune disease. Management has also indicated that current ca-sh resources are expected to fund operations through the fourth quarter of 2026.

When you combine multiple clinical catalysts, platform versatility, and a market capitalization below $12M, GTBP stands out as a biotech story worth watching closely.

We’ll be monitoring (GTBP) closely tomorrow morning.

Take a closer look at GTBP before the evening is over.

And keep an eye on your inbox—our full morning update may arrive earlier than expected.

Sincerely,
Tate Remington
Chief Editor, Market Maven Insights

^{MarketMavenInsights.com}^{(“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.}

^{Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 05/13/2026 and ending on 05/14/2026 to publicly disseminate information about (GTBP:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC seven thousand five hundred USD (“Funds”). These Funds were part of the one hundred fifty thousand USD funds that TD Media LLC received from GT Biopharma Inc., the issuer of (GTBP:US).}

^{Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (GTBP:US).}

^{Please see important disclosure information here:}^{https://marketmaveninsights.com/disclosure/gtbp-7EFK4/#details}